Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

WASHINGTON — Sen. Bernie Sanders, I-Vt., on Tuesday extracted a meager commitment from Novo Nordisk CEO Lars Fruergaard Jørgensen to meet with pharmacy benefits managers to discuss lowering the ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor ...

When told by Sanders that the three leading PBMs had agreed to not reduce access to Ozempic and Wegovy should Novo Nordisk substantially cut the cost, the executive said he'd be open to ...

Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products Ozempic is currently covered by 99% of commercial insurance plans, plus Medicare and Medicaid ...

Presented by Prevent Cancer Foundation — The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss drugs Ozempic and Wegovy ...

Sept. 24 (UPI) --The CEO of Novo Nordisk is on Capitol Hill Tuesday to testify before a Senate committee about the high costs of its drugs Ozempic and Wegovy.Chairman Sen. Bernie Sanders, I-Vt ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk's stock is still up more than 250% since Jørgensen took over as CEO in January 2017. But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took ...